Canadian Society for Pharmaceutical Sciences
Société canadienne des sciences pharmaceutiques


Renowned Speakers Headline Virtual COVID-19 Event

COVID-19: Current Pharmaceutical Developments for Cures and Prevention, a members-only, multi-date event is an in-depth exploration of the pharmaceutical sciences during the current pandemic. It opens and closes with sessions featuring two of the most respected leaders in the field.

April 27–28 and May 11–12      

A conversation with William Haseltine, Ph.D., ACCESS Health International
Opening Session—April 27, 11:00 am
Managing an Infectious Disease Pandemic: Historic Lessons, Current and Future Approaches
This moderated session draws on Dr. Haseltine’s experience working on HIV, as well as developing one of the first countermeasure biotherapeutics that became part of the U.S. BioShield preparedness effort. He will offer his perspectives on the current crisis—from detecting and containing the spread of the disease, to countermeasures and the overall public health response.

Dr. Haseltine is an eminent scientist, businessman, author, and philanthropist known for his pioneering work on cancer, HIV/AIDS, and genomics. A former professor, he is the founder of more than a dozen biotechnology companies, and currently serves as chair and president of ACCESS Health International, Inc.

Roundtable discussion moderator Ronald Piervincenzi, Ph.D., United States Pharmacopeia
Closing Session—May 12, 1:30 pm
The Global Supply Chain—Vulnerabilities, Need for Transparency, and Building Resilience in the Supply Chain
This session focuses on the vulnerabilities of the global medicine supply chain that have been exposed by the current pandemic and shares relevant data in order to bring greater transparency to ensure the quality and safety of medicines.

Dr. Piervincenzi is chief executive officer of USP and provides strategic leadership to a global staff of over 1,200 across 10 sites around the world. He brings more than 25 years of industry experience across the pharmaceutical sciences from research to business strategy.